Is an organism reported as sensitive to cefazolin and to Cephara (cephalexin) likely also sensitive to Keflex (cephalexin)?

Cefazolin Sensitivity Does NOT Predict Cephalexin (Keflex) Sensitivity

An organism sensitive to cefazolin cannot be assumed to be sensitive to cephalexin (Keflex), and susceptibility testing for each agent should be performed separately when clinically indicated. These are distinct first-generation cephalosporins with different antimicrobial spectra, pharmacokinetic properties, and clinical applications that require independent susceptibility determination.

Key Microbiological Differences

Spectrum of Activity Divergence

• Cefazolin demonstrates superior activity against gram-negative organisms, particularly Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, with 2- to 8-fold greater potency than cephalexin against these pathogens 1.
• Cephalexin shows weaker gram-negative coverage, with 57.5% of gram-negative bacilli resistant to cephalexin compared to only 39% resistant to cefazolin in clinical isolate studies 2.
• Against gram-positive cocci, cefazolin achieves 71.8% susceptibility rates versus 52.7% for cephalexin 2.

Bacteroides fragilis Susceptibility

• Cefazolin inhibits 94% of Bacteroides fragilis strains at achievable blood concentrations, while only 22% of strains are susceptible to cephalexin 3.
• This represents a critical difference for intra-abdominal and anaerobic infections where cross-susceptibility cannot be assumed.

Pharmacokinetic and Tissue Penetration Differences

Serum Concentrations and Half-Life

• Cefazolin achieves significantly higher and more sustained serum levels: peak concentrations of 38.8 mcg/mL after 1g intramuscular injection with detectable levels at 8 hours (half-life 2 hours) 1.
• Cephalexin produces lower peak levels of approximately 18 mcg/mL after 500mg oral administration with shorter duration 4.

Tissue Penetration

• Cefazolin demonstrates superior prostatic tissue penetration and frequently exceeds minimum inhibitory concentrations (MICs) for sensitive organisms, whereas cephalexin does not achieve therapeutic levels in prostatic tissue 5.
• This pharmacokinetic disparity means organisms may be clinically susceptible to cefazolin but fail to respond to cephalexin due to inadequate drug concentrations at the infection site.

Clinical Laboratory Standards

Susceptibility Testing Requirements

• The FDA label for Keflex explicitly states that susceptibility testing uses cephalothin (not cefazolin) as the class representative for disk diffusion and MIC determination 4.
• Cefazolin susceptibility testing follows separate standardized protocols with distinct interpretive criteria 6.
• MIC breakpoint distributions differ significantly between these agents, with cefazolin showing different resistance patterns particularly for E. coli where the susceptible breakpoint bisects the wild-type MIC distribution 7.

Cross-Resistance Patterns

• Studies demonstrate that 39% of isolates resistant to cefazolin may still show intermediate or full susceptibility to other first-generation cephalosporins due to varying MIC distributions 2.
• The converse is also true: organisms susceptible to cefazolin may demonstrate resistance to cephalexin, particularly among gram-negative bacilli.

Clinical Implications for Antibiotic Selection

When Cefazolin is Preferred

• Parenteral therapy for serious infections including bacteremia, endocarditis, bone/joint infections, and surgical prophylaxis where cefazolin is the standard of care 6.
• Gram-negative infections where cefazolin's superior activity against E. coli, Klebsiella, and Proteus species is clinically relevant 8.
• Intra-abdominal or anaerobic coverage where Bacteroides susceptibility is required 3.

When Cephalexin May Be Appropriate

• Oral step-down therapy for mild-to-moderate skin and soft tissue infections caused by Staphylococcus aureus or Streptococcus pyogenes 9.
• Outpatient management of uncomplicated urinary tract infections where oral administration is preferred 4.
• Pediatric infections including acute otitis media, community-acquired pneumonia, and pharyngitis when amoxicillin is unavailable, though clinical outcomes should be monitored 10.

Penicillin Allergy Considerations (Addressing "Cephara Axone" Confusion)

Clarification of Drug Names

• "Cephara" likely refers to cephalexin (a common brand name variant).
• "Axone" likely refers to ceftriaxone (brand name Rocephin), a third-generation cephalosporin with entirely different spectrum and indications.
• These are distinct agents that should not be conflated in susceptibility reporting.

Cross-Reactivity with Penicillins

• Cefazolin has a unique R1 side chain with very low cross-reactivity to penicillins (0.7-3.0% in patients with confirmed penicillin allergy), making it safe for most penicillin-allergic patients including those with anaphylaxis history 11, 12, 13.
• Cephalexin shares R1 side chains with aminopenicillins (amoxicillin/ampicillin), resulting in significantly higher cross-reactivity rates of approximately 16.5% in patients with confirmed aminopenicillin allergy 11.
• This structural difference means penicillin allergy implications differ substantially between cefazolin and cephalexin, further emphasizing they should not be treated as interchangeable.

Practical Recommendations

Laboratory Reporting

• Microbiology laboratories should report susceptibilities for cefazolin and cephalexin separately when both are tested, as results for one agent do not predict the other.
• Clinicians should not extrapolate cefazolin susceptibility to assume cephalexin coverage, particularly for gram-negative infections.

Antimicrobial Stewardship

• Definitive therapy should be guided by organism-specific susceptibility testing rather than class-based assumptions 6.
• When transitioning from parenteral cefazolin to oral therapy, repeat susceptibility testing for oral agents (including cephalexin) should be considered for serious infections or when clinical response is suboptimal.
• Cephalexin represents a narrower-spectrum alternative to amoxicillin-clavulanate for appropriate indications, supporting antimicrobial stewardship goals 10.

Clinical Monitoring

• Treatment failure rates may differ between agents even when both show in vitro susceptibility, particularly at higher MIC values (e.g., cefazolin MIC of 8 mcg/mL shows trends toward increased treatment failure) 14.
• Monitor for clinical response when switching between cephalosporins, as pharmacokinetic differences may result in therapeutic failure despite reported susceptibility.